We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Breakthrough in Stem Cell Culturing Without the Use of Animal Substances

By LabMedica International staff writers
Posted on 01 Jul 2010
For the first time, human embryonic stem cells have been cultured under chemically controlled conditions without the use of animal substances, which is vital for future clinical uses. More...


The method, developed by researchers from Karolinska Institutet (Stockholm, Sweden), was published online May 30, 2010, in the journal Nature Biotechnology. Embryonic stem cells can be transformed into any other type of cell in the body and have potential uses in treatments where sick cells need to be replaced. One hurdle, however, is that it is difficult to culture and develop human embryonic stem cells without simultaneously contaminating them. They are currently cultured with the aid of proteins from animals, which eliminates subsequent use in the treatment of humans. Alternatively, the stem cells can be cultured on other human cells, known as feeder cells, but these release thousands of uncontrolled proteins and therefore lead to ineffective research results.

A research team at Karolinska Institutet has now managed to produce human stem cells entirely without the use of other cells or substances from animals. Instead, they are cultured on a matrix of a single human protein: laminin-511. "Now, for the first time, we can produce large quantities of human embryonic stem cells in an environment that is completely chemically defined,” stated Prof. Karl Tryggvason, who led the study. "This opens up new opportunities for developing different types of cell which can then be tested for the treatment of disease.”

Together with researchers at the Harvard Stem Cell Institute (Cambridge, MA, USA), the investigators have also shown that in the same way they can culture what are known as reprogrammed stem cells, which have been converted "back” from tissue cells to stem cells.

Laminin-511 is part of connective tissue and acts in the body as a matrix to which cells can attach. In the newly formed embryo, the protein is also needed to keep stem cells as stem cells. Once the embryo begins to develop different types of tissue, other types of laminin are needed.

Until now, different types of laminin have not been available to researchers, because they are nearly impossible to extract from tissues and difficult to generate. Over the last couple of decades, Prof. Tryggvason's research group has cloned the genes for most human laminins, examined their biologic role, described two genetic laminin diseases, and in recent years, even managed to produce several types of laminin using gene technology. In this latest project, the researchers produced the laminin-511 using recombinant techniques.

Related Links:
Karolinska Institutet
Harvard Stem Cell Institute




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.